Bright Minds Biosciences (DRUG) Intangibles (2020 - 2022)

Bright Minds Biosciences (DRUG) has 3 years of Intangibles data on file, last reported at $1568.7 in Q2 2022.

• Quarterly Intangibles fell 3.59% year-over-year to $1568.7 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $1568.7 (down 3.59% YoY) and the FY2021 annual result came in at $1588.8, up 5.86% from the prior year.
• Intangibles retreated to $1568.7 in Q2 2022, from $1579.0 in the prior quarter.
• In the past five years, Intangibles ranged from a high of $1627.1 in Q2 2021 to a low of $1500.8 in Q3 2020.
• A 3-year average of $1575.2 and a median of $1582.8 in 2021 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2021 — Intangibles grew 5.86% — and 2022, when it retreated 3.59%.
• Tracing DRUG's Intangibles over 3 years: stood at $1500.8 in 2020, then advanced by 5.72% to $1586.7 in 2021, then retreated by 1.13% to $1568.7 in 2022.
• The last three Intangibles figures came in at $1568.7 (Q2 2022), $1579.0 (Q1 2022), and $1586.7 (Q4 2021), per Business Quant data.